• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott wins EUA for COVID-19 test that runs off a card

Abbott wins EUA for COVID-19 test that runs off a card

August 27, 2020 By Chris Newmarker

Abbott's BinaxNow COVID-19 Ag Card COVID-19 corona virus
Abbott’s BinaxNow COVID-19 Ag Card [Image courtesy of Abbott]
FDA has announced an emergency use authorization for Abbott’s BinaxNow COVID-19 Ag Card — a speedy antigen test for the virus that can be directly read off the testing card.

The agency in the announcement yesterday evening compared the test’s design to some pregnancy tests. A healthcare provider swabs the patient’s nose and twirls the sample on a test card with a testing reagent added. After waiting 15 minutes, the card displays a result: one line for a negative result and two for a positive result.

Abbott (NYSE:ABT) stock is up nearly 9% today, trading at more than $112 per share in afternoon trading. Stocks of other major companies in the COVID-19 testing space took a big hit — including Quidel (NSDQ: QDEL), –26%; Quest Diagnostics (NYSE:DGX) –7.6%; and Hologic (NSDQ:HOLX), –6%. Abbott’s announcement could wipe out at least $22 billion in market value across more than a dozen companies, according to Bloomberg.

Abbott says a clinical study conducted at several leading U.S. research universities showed that the BinaxNow has 97.1% sensitivity (positive percent agreement) and 98.5% specificity (negative percent agreement) among people with suspected COVID-19 cases seeking tests within seven days of exhibiting symptoms.

Abbott plans to ship tens of millions of tests in September, ramping to 50 million tests a month at the start of October. They’ll sell for $5 apiece.

“Due to its simpler design and the large number of tests the company anticipates making in the coming months, this new antigen test is an important advancement in our fight against the pandemic,” said Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health.

Abbott is touting BinaxNow as a way for schools and other organizations to help keep people in facilities safe. The tests come with a free mobile app called Navica that allows people who test negative to display a temporary digital health pass that includes the date of the health result. The health pass gets renewed every time they test again and come up negative.

“We intentionally designed the BinaxNow test and Navica app so we could offer a comprehensive testing solution to help Americans feel more confident about their health and lives,” Abbott CEO Robert B. Ford said in a news release. “BinaxNow and the Navica app give us an affordable, easy-to-use, scalable test, and a complementary digital health tool to help us have a bit more normalcy in our daily lives.”

This story originally ran on the evening of Aug. 26, 2020. Updated Aug. 27 with the effect on medtech company stocks. 

 

 

Filed Under: Diagnostics, Digital Health, Featured, Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Abbott, coronavirus, COVID-19, FDA

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy